Therapeutic Potential of DNA-aptamers Raised Against AGE-RAGE Axis in Diabetes-related Complications

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Advanced glycation end products (AGEs) accumulate in diabetes, contributing to complications like nephropathy, retinopathy, cardiovascular disease, insulin resistance, cancer, osteoporosis, and Alzheimer's disease.
• AGEs modify proteins, lipids, and nucleic acids, altering function and triggering oxidative stress and inflammation via the receptor for AGEs (RAGE).
• The AGE-RAGE axis is implicated in numerous disorders, making it a potential therapeutic target for diabetes- and aging-related conditions.

Purpose of the Study:

• To review the therapeutic potential of DNA aptamers targeting the AGE-RAGE axis.
• To focus on applications in diabetes-associated complications, particularly vascular complications and cancer.

Main Methods:

• Review of existing literature on AGEs, RAGE, and aptamer technology.
• Discussion of aptamer generation, specificity, affinity, and potential advantages over antibodies.
• Exploration of the therapeutic strategies involving DNA aptamers against the AGE-RAGE axis.

Main Results:

• Aptamers are short oligonucleotides with high specificity and affinity for target proteins.
• Aptamers offer advantages such as ease of generation, organ penetration, and low risk of allergic reactions compared to antibodies.
• DNA aptamers targeting the AGE-RAGE axis show therapeutic potential for diabetes-related vascular complications and cancer.

Conclusions:

• Inhibition of the AGE-RAGE axis is a viable therapeutic strategy for diabetes- and aging-related disorders.
• DNA aptamers represent a promising class of therapeutics for targeting the AGE-RAGE axis.
• Further research into DNA aptamers for AGE-RAGE related diseases, especially vascular complications and cancer, is warranted.